Madrigal Pharmaceuticals (MDGL) Receivables - Net (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Receivables - Net of $192.3 million for Q2 2026, up 142.72% year-over-year from $79.2 million in Q2 2025, and up 2.64% quarter-over-quarter from $187.4 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Receivables - Net (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Receivables - Net for 4 consecutive years, with $192.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables - Net rose 142.72% year-over-year to $192.3 million; the TTM figure through Jun 2026 stood at $192.3 million (up 142.72% YoY), while the FY2025 annual figure was $134.5 million, up 149.85% from the prior year.
- Receivables - Net grew to $192.3 million in Q2 2026 per MDGL's latest filing, from $187.4 million in the prior quarter.
- Across five years, Receivables - Net topped out at $192.3 million in Q2 2026 and bottomed at $6.9 million in Q2 2024.
- Historically, Receivables - Net has averaged $95.5 million across 3 years, with a median of $79.2 million in 2025.
- Annual changes were most pronounced in 2025 — Receivables - Net surged 1048.44% — and 2026, when it jumped 142.72%.
- Madrigal Pharmaceuticals' Receivables - Net stood at $53.8 million in 2024, then soared by 149.85% to $134.5 million in 2025, then soared by 43.01% to $192.3 million in 2026.
- Business Quant data shows MDGL's Receivables - Net at $192.3 million in Q2 2026, $187.4 million in Q1 2026, and $134.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.31 Mn |
| Jun 30, 2026 | 192.31 Mn |
| Mar 31, 2026 | 187.36 Mn |
| Mar 31, 2026 | 187.36 Mn |
| Dec 31, 2025 | 134.48 Mn |
| Dec 31, 2025 | 134.48 Mn |
| Sep 30, 2025 | 113.29 Mn |
| Sep 30, 2025 | 113.29 Mn |
| Jun 30, 2025 | 79.23 Mn |
| Jun 30, 2025 | 79.23 Mn |
| Mar 31, 2025 | 61.43 Mn |
| Mar 31, 2025 | 61.43 Mn |
| Dec 31, 2024 | 53.82 Mn |
| Dec 31, 2024 | 53.82 Mn |
| Sep 30, 2024 | 30.46 Mn |
| Sep 30, 2024 | 30.46 Mn |
| Jun 30, 2024 | 6.90 Mn |
| Jun 30, 2024 | 6.90 Mn |
| Dec 31, 2010 | 116,000.00 |
| Dec 31, 2010 | 116,000.00 |